利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.025 秒)

    Human antibodies to Bet v 1 and methods of use thereof
    2.
    发明授权
    Human antibodies to Bet v 1 and methods of use thereof 有权

    公开(公告)号：US10793624B2

    公开(公告)日：2020-10-06

    申请号：US15994294

    申请日：2018-05-31

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jamie M. Orengo ,  Andrew J. Murphy ,  Ashok T. Badithe ,  Vishal Kamat ,  Yashu Liu

    IPC分类号： C07K16/16 ,  A61P37/08 ,  A61K39/00 ,  A61K39/395

    摘要： Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.

    Anti-IL-25 antibodies and uses thereof
    6.
    发明授权
    Anti-IL-25 antibodies and uses thereof 有权

    公开(公告)号：US11542326B2

    公开(公告)日：2023-01-03

    申请号：US16803582

    申请日：2020-02-27

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jamie M. Orengo ,  Jeanne Allinne

    IPC分类号： C07K16/24 ,  A61K39/395 ,  C12N15/09 ,  C12N15/11 ,  A61K45/06 ,  A61K39/00

    摘要： The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.

    Anti-IL-33 antibodies and uses thereof
    7.
    发明授权
    Anti-IL-33 antibodies and uses thereof 有权

    公开(公告)号：US11104729B2

    公开(公告)日：2021-08-31

    申请号：US16687257

    申请日：2019-11-18

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Andrew J. Murphy ,  Nicholas J. Papadopoulos ,  Jamie M. Orengo

    IPC分类号： C07K16/24 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

    摘要： The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
    8.
    发明授权
    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof 有权

    公开(公告)号：US10851158B2

    公开(公告)日：2020-12-01

    申请号：US15985660

    申请日：2018-05-21

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jamie M. Orengo ,  Jeanne Allinne ,  Wen Fury ,  Yu Bai

    IPC分类号： A61K39/395 ,  C07K16/24 ,  C07K14/575 ,  A61K38/17 ,  A61K45/06 ,  C07K14/715 ,  G01N33/68 ,  A61K39/00

    摘要： The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.